Seki 2022: Brown Fat, the Warburg Effect, and the Cold-Plunges-Cure-Cancer Overclaim

Seki et al. 2022 in Nature (Karolinska Institutet, Per-Olof Berggren's group) titled 'Brown-fat-mediated tumour suppression by cold-altered global metabolism' is the original source for the 'cold plunges cure cancer' claim that proliferated on social media. In mice, continuous 4°C exposure dramatically slowed tumor growth across melanoma, colorectal, pancreatic, and breast cancer models. The mechanism: BAT activation drove a roughly 25-fold increase in glucose uptake per gram of fat, lowering systemic blood glucose and starving tumors dependent on the Warburg effect — the preference of many cancers for aerobic glycolysis over oxidative phosphorylation even in oxygen-rich conditions. Adding exogenous glucose partially reversed the tumor suppression, confirming the glucose-starvation mechanism. A single human Hodgkin's lymphoma patient was exposed to mild cold (around 22°C) for about seven days. PET-CT showed increased BAT activity and decreased tumor glucose uptake. This was mechanistic confirmation, not an efficacy or cure demonstration — single patient, no control, no outcome claim. The compression from this paper to 'cold plunges cure cancer' involves several large extrapolation errors. Mice were held at 4°C continuously for weeks; a human at 4°C continuously would be hypothermic within hours. Huberman-style protocols of 11 minutes per week at 10-15°C are orders of magnitude less cold stress. Mice carry 1-5% BAT by body mass; adult humans carry 0.05-0.1% even after training. The glucose-sink mechanism scales with BAT mass, so mouse results do not extrapolate linearly. No human RCTs of cold exposure as cancer treatment exist as of 2026. Cancers are also metabolically flexible. Many can switch to glutamine (common in aggressive tumors), ketones (which is why ketogenic diets have mixed cancer results), lactate via reverse Warburg in some stromal interactions, or fatty acids directly. Purely glucose-restricting approaches — ketogenic diet, 2-deoxyglucose, metformin — have produced mixed rather than uniform results in cancer trials for exactly this reason. The patient-harm risk is concrete. Johnson et al. 2018 in JNCI documented that alternative-medicine-only cancer treatment carried roughly 2.5x the mortality of conventional treatment. The Seki paper is legitimate preclinical work; substituting cold exposure for chemotherapy or surgery on the basis of it is dangerous.